Journal of Cancer Research and Clinical Oncology

, Volume 133, Issue 11, pp 897–901 | Cite as

Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma

  • Patrick TerheydenEmail author
  • Maja Ann Hofmann
  • M. Weininger
  • Eva-B. Bröcker
  • Jürgen C. Becker
Letter to the Editor



The combination of the antiangiogenic antibody bevacizumab with standard chemotherapy has improved the prognosis in patients with metastastic colorectal cancer and other advanced cancers. The role of combined anti-VEGF and chemotherapy in metastastic melanoma is just starting to be elucidated.


We tested this notion in three patients with advanced and therapy-refractory melanoma.


Interestingly, two patients achieved objective regressions after three courses of therapy; the third patient, albeit progressing demonstrated a pronounced liquid necrosis in bulky lymphnode metastasis.


Further studies are warranted to scrutinise these impressive therapeutic effects on the combination of bevacizumab and chemotherapy in melanoma.


Melanoma Metastases Therapy Angiogenesis Chemotherapy 


  1. Beierle EA, Nagaram A, Dai W, Iyenger M, Chen MK (2005) VEGF-mediated survivin expression in neuroblastoma cells. J Surg Res 127:21–28PubMedCrossRefGoogle Scholar
  2. Brennecke S, Deichmann M, Naeher H, Kurzen H (2005) Decline of angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastastic melanoma. Melanoma Res 15:515–522PubMedCrossRefGoogle Scholar
  3. Demirkesen C, Buyukpinarbasili H, Ramazanoglu R, Oguz O, Mandel NM, Kaner G (2006) The correlation of angiogenesis with metastasis in primary cutaneous melanoma: a comparative analysis of microvessel density, expression of vascular endothelial growth factor and basic fibroblast growth factor. Pathology 38:132–137PubMedCrossRefGoogle Scholar
  4. Eigentler TK, Caroli UM, Radny P, Garbe C (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4:748–759PubMedCrossRefGoogle Scholar
  5. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391–400PubMedCrossRefGoogle Scholar
  6. Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65:671–680PubMedGoogle Scholar
  7. Giatromanolaki A, Sivridis E, Koukourakis MI (2006) Angiogenesis in colorectal cancer: prognostic and therapeutic implications. Am J Clin Oncol 29:408–417PubMedCrossRefGoogle Scholar
  8. Gille J (2006) Antiangionenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. Exp Dermatol 15:175–186PubMedCrossRefGoogle Scholar
  9. Güven K, Kittler H, Wolff K, Pehamberger H (2001) Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine resistant melanoma patients. Melanoma Res 11:411–415PubMedCrossRefGoogle Scholar
  10. Hicklin DJ, Ellis LM (2005) Role of vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027PubMedCrossRefGoogle Scholar
  11. Houben R, Becker JC, Kappel A, Terheyden P, Bröcker EB, Götz R, Rapp UR (2004) Constitutive activation of the Ras-Raf signaling pathway in metastastic melanoma is associated with poor prognosis. J Carcinog 3:6PubMedCrossRefGoogle Scholar
  12. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluororuracil, and leucovorin for metastastic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRefGoogle Scholar
  13. Lev DC, Ruiz M, Mills L, McGary EC, Price JC, Bar-Eli M (2003) Dacarbazine causes transcriptional up-regulation of interleukin-8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther 2:753–763PubMedGoogle Scholar
  14. Passagne I, Evrard A, Depeille P, Cuq P, Cupissol D, Vian L (2006) O6-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C. Toxicol Appl Pharmacol 211:97–105PubMedCrossRefGoogle Scholar
  15. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550PubMedCrossRefGoogle Scholar
  16. Shih T, Lindley C (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28:1779–1802PubMedCrossRefGoogle Scholar
  17. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y (2006) The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203:1651–1656PubMedCrossRefGoogle Scholar
  18. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731–3736PubMedCrossRefGoogle Scholar
  19. Tran J, Rak J, Sheehan C, Saibil SD, LaCasse E, Korneluk RE, Kerbel RS (1999) Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 264:781–788PubMedCrossRefGoogle Scholar
  20. Ugurel S, Rappl G, Tilgen W, Reinhold U (2001) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19:577–583PubMedGoogle Scholar
  21. Weis SM, Cheresh DA (2005) Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437:497–504PubMedCrossRefGoogle Scholar
  22. Zhang L, Hannay JAF, Liu J, Das P, Zhan M, Nguyen T, Hicklin DJ, Yu D, Pollock RE, Lev D (2006) Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumour growth, metastasis , and chemoresistance. Cancer Res 66:8770–8778PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Patrick Terheyden
    • 1
    Email author
  • Maja Ann Hofmann
    • 2
  • M. Weininger
    • 3
  • Eva-B. Bröcker
    • 1
  • Jürgen C. Becker
    • 1
  1. 1.Department of Dermatology, Venerology and AllergologyUniversity of WürzburgWürzburgGermany
  2. 2.Department of Dermatology and AllergyCharité, Universitätsmedizin BerlinBerlinGermany
  3. 3.Department of RadiologyUniversity of WürzburgWürzburgGermany

Personalised recommendations